With the Pharmaceutical Price Regulation Scheme (PPRS) being renegotiated, Leela Barham looks at the trends in National Institute for Health and Care Excellence (NICE) recommendations and asks
How has the UK compared to its European peers in terms of supporting growth and innovation in the pharmaceutical sector? And with a renegotiation of the PPRS pricing deal imminent, Leela Barha
In the final part of a series of five articles looking at the current Pharmaceutical Price Regulation Scheme (PPRS), Leela Barham focuses on whether it has achieved the goal o
In the fourth in her series of five articles looking at the objectives of the PPRS, Leela Barham focuses on whether the Pharmaceutical Price Regulation Scheme (PPRS) has delivered on the aim of
In the third in her series of five articles, Leela Barham considers the extent to which the third of the UK PPRS’ objectives – to keep the branded medicines bill within affordable limits – has
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas